Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Depression
Interventions
DRUG

BMS-866949

(Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days

DRUG

BMS-866949

(Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days

DRUG

BMS-866949

(Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days

DRUG

BMS-866949

(Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days

DRUG

BMS-866949

(Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days

DRUG

BMS-866949

(Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days

DRUG

BMS-866949

(Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days

DRUG

Placebo

(Matching volume) - Oral Solution, Oral, once 14 days

Trial Locations (1)

751 23

Local Institution, Uppsala

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY